Natera

A new prospective study in Clinical Cancer Research highlights how Signatera™ was able to identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy (pET), without surgery. Patients enrolled in the study were aged 70 and older, all with stage 1-3 ER+/HER2- breast cancer, and all of whom elected to forgo surgery and receive pET. Signatera identified that 68% of patients were MRD-negative before treatment, meaning they had no signs of molecular disease. Notably, none of those patients experienced progression of their cancer during the trial — an incredibly strong result. The study also showed that over 80% of patients reported that Signatera helped inform their treatment decisions without increased anxiety. This paper adds to the growing body of evidence showing Signatera's significant impact in breast cancer, as well as Natera's efforts to help clinicians and patients make more informed decisions in cancer management. You can read more in our press release: https://ow.ly/ZyoP50YBV7K

This video reflects on the progress we’ve made, with a gracious nod to what comes next at Natera. It brings together different perspectives, from how the outside world sees our work, to the voices of patients and families sharing what this experience looks like in their own words. It also reflects the work happening behind the scenes across teams and disciplines. Most of us know someone impacted by cancer, planning for a baby, or navigating life after a transplant. It’s something we think about every day, and we’re honored to support people through some of life’s most important moments. We’re proud of the progress. Grateful for the trust patients place in us. And clear on how much more there is to do. If you have a few minutes, it’s worth a watch.

The ability to detect phased variants – two or more single nucleotide variants (SNVs) co-occurring on the same DNA molecule – is redefining ultrasensitive limits of detection for minimal residual disease (MRD). Because the likelihood of these linked mutations arising by chance is extremely low, phased variants support enhanced error suppression and increase confidence in variant calls at very low allele frequencies. Signatera™ Genome RUO now integrates PhasED-Seq™, a proprietary phased variant detection technology originally developed at Foresight Diagnostics (now part of Natera), delivering ultrasensitive MRD detection at scale to our pharmaceutical and research partners. In this webinar, Max Diehn, MD, PhD, co-founder of Foresight Diagnostics, will provide an overview of PhasED-Seq™ technology, clinical data highlights and promising applications. An expert Q&A session with Dr. Diehn, David Kurtz, MD, PhD, David Shames, PhD, Minetta Liu, MD, and John Simmons will follow. Register here: https://ow.ly/zIOP50YAMJN

After completing definitive treatment, many breast cancer survivors look to their OB/GYN with questions about recurrence risk, lingering symptoms and appropriate follow-up. Join us on April 2 at 4 PM PT | 7 PM ET for an expert-led discussion on breast cancer surveillance after definitive treatment. Amber Shamburger, MD, Nicole Scott, MS, PA-C, and Adam ElNaggar, MD will focus on how OB/GYNs can support survivors in the post-therapy setting, address common patient questions and thoughtfully approach monitoring for recurrence in patients with a prior breast cancer diagnosis. If you work with breast cancer survivors or collaborate with OB/GYNs, this conversation may be valuable to your network. Please share with colleagues who would benefit. Register here: https://ow.ly/BEmo50YyUol

March 22 is Lynch Syndrome Awareness Day. Today, we’re standing with the hereditary cancer community to raise awareness, share resources, and encourage proactive conversations about risk and screening. What to know: Lynch syndrome is an inherited condition caused by changes in these genes: EPCAM, MLH1, MSH2, MSH6 and PMS2. People with Lynch are at increased risk for colorectal, endometrial and other cancers. Take action: ✔️ Learn your family history and discuss it with your healthcare provider. ✔️ Ask about genetic counseling and testing if Lynch syndrome runs in your family. ✔️ Follow a screening plan that fits your risk Awareness, action and support make prevention possible. Together, we can ensure that no one faces hereditary cancer alone. We’re honored to collaborate with partners in this effort, including Man Up to Cancer, Lynch Syndrome Awareness and AliveandKick’n, to amplify life‑saving information. 💙 #LynchSyndrome #ColorectalCancerAwareness #KnowYourRisk #GeneticTesting #HereditaryCancer #FacingOurRisk MAN UP TO CANCER Lynch Syndrome Awareness and Education, AliveAndKickn

Proud to sponsor this event leading up to ISHLT - International Society for Heart and Lung Transplantation's annual meeting. #ISHLT2026

Proud to support the National Kidney Foundation at the 43rd Annual Great Chefs of the West. Our team joined an inspiring event dedicated to advancing research, expanding patient support and increasing education for those affected by kidney disease. This work is so important. Approximately 37 million U.S. adults are estimated to have kidney disease, and up to 1 in 5 people with kidney disease may have a genetic cause. https://ow.ly/3xJx50YwY0m

Dr. Justin Rosenheck discusses findings from the QAPI study evaluating Natera’s Prospera™ Lung transplant assessment, published in Transplantation Direct by The Transplantation Society (TTS). “This study highlights how monitoring with Prospera can improve both the patient experience and the sustainability of transplant programs,” said Dr. Rosenheck, clinical assistant professor of internal medicine at The Ohio State University Wexner Medical Center and principal investigator of the study. “These compelling results support our goal of providing more personalized and efficient medical care without compromising patient safety or outcomes.” Watch the full presentation: https://ow.ly/oMoU50YiaQB #Natera

Minetta Liu, MD, chief medical officer for Natera oncology, recently participated in two panel discussions about the importance of molecular residual disease testing during the Precision Medicine World Conference. The panelists discussed the role of circulating tumor DNA in recurrence monitoring and its potential utilization in therapy and treatment decisions in the future. Learn more about Signatera™ during our upcoming webinars: https://ow.ly/6Wjq50Yvxy3 #PMWC26 #Natera #ctDNA #MRDtesting